112 related articles for article (PubMed ID: 15477875)
41. [131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma.
McCluskey AG; Boyd M; Gaze MN; Mairs RJ
Cancer Lett; 2005 Oct; 228(1-2):221-7. PubMed ID: 15935554
[TBL] [Abstract][Full Text] [Related]
42. Assessment in vitro of a novel therapeutic strategy for glioma, combining herpes simplex virus HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.
Quigg M; Mairs RJ; Brown SM; Harland J; Dunn P; Rampling R; Livingstone A; Wilson L; Boyd M
Med Chem; 2005 Sep; 1(5):423-9. PubMed ID: 16787326
[TBL] [Abstract][Full Text] [Related]
43. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
Gulley JL; Arlen PM; Bastian A; Morin S; Marte J; Beetham P; Tsang KY; Yokokawa J; Hodge JW; Ménard C; Camphausen K; Coleman CN; Sullivan F; Steinberg SM; Schlom J; Dahut W
Clin Cancer Res; 2005 May; 11(9):3353-62. PubMed ID: 15867235
[TBL] [Abstract][Full Text] [Related]
44. Combining gene and immunotherapy for prostate cancer.
Young JG; Green NK; Mautner V; Searle PF; Young LS; James ND
Prostate Cancer Prostatic Dis; 2008; 11(2):187-93. PubMed ID: 17726452
[TBL] [Abstract][Full Text] [Related]
45. [A study on selective killing effect of Hsv-tk/GCV driven by human telomerase catalytic subunit promoter on human lung cancer cell A549].
Tang XJ; Wang YP; Zhou QH; Che GW; Chen XH; Zhu DX
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Apr; 24(2):148-52. PubMed ID: 17407070
[TBL] [Abstract][Full Text] [Related]
46. Radiation enhances suicide gene therapy in radioresistant laryngeal squamous cell carcinoma via activation of a tumor-specific promoter.
Liao Z; Huang C; Zhou F; Xiong J; Bao J; Zhang H; Sun W; Xie C; Zhou Y
Cancer Lett; 2009 Sep; 283(1):20-8. PubMed ID: 19375219
[TBL] [Abstract][Full Text] [Related]
47. Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer.
Lu Y
Adv Drug Deliv Rev; 2009 Jul; 61(7-8):572-88. PubMed ID: 19393705
[TBL] [Abstract][Full Text] [Related]
48. Hypoxia- and radiation-activated Cre/loxP 'molecular switch' vectors for gene therapy of cancer.
Greco O; Joiner MC; Doleh A; Powell AD; Hillman GG; Scott SD
Gene Ther; 2006 Feb; 13(3):206-15. PubMed ID: 16307003
[TBL] [Abstract][Full Text] [Related]
49. Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity.
Ouchi H; Ishiguro H; Ikeda N; Hori M; Kubota Y; Uemura H
Int J Urol; 2005 Jan; 12(1):73-80. PubMed ID: 15661057
[TBL] [Abstract][Full Text] [Related]
50. Prostate cancer stem cells, telomerase biology, epigenetic modifiers, and molecular systemic therapy for the androgen-independent lethal phenotype.
Koeneman KS
Urol Oncol; 2006; 24(2):119-21. PubMed ID: 16520275
[TBL] [Abstract][Full Text] [Related]
51. Tightly-regulated suicide gene expression kills PSA-expressing prostate tumor cells.
Peng W; Chen J; Huang YH; Sawicki JA
Gene Ther; 2005 Nov; 12(21):1573-80. PubMed ID: 16034457
[TBL] [Abstract][Full Text] [Related]
52. Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer.
Copp H; Bissonette EA; Theodorescu D
Urology; 2005 Jun; 65(6):1146-51. PubMed ID: 15922433
[TBL] [Abstract][Full Text] [Related]
53. Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Zhong S; Liu X; Tan WS
J Gene Med; 2008 May; 10(5):518-26. PubMed ID: 18338833
[TBL] [Abstract][Full Text] [Related]
54. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer.
Fujita T; Timme TL; Tabata K; Naruishi K; Kusaka N; Watanabe M; Abdelfattah E; Zhu JX; Ren C; Ren C; Yang G; Goltsov A; Wang H; Vlachaki MT; Teh BS; Butler EB; Thompson TC
Gene Ther; 2007 Feb; 14(3):227-36. PubMed ID: 17024109
[TBL] [Abstract][Full Text] [Related]
55. [All-trans retinoic acid enhances bystander effect of suicide-gene therapy against androgen-unresponsive prostate cancer].
Chen WG; Yan CY; Hou JQ; Wen DG; Pu JX; Wang HB
Zhonghua Nan Ke Xue; 2008 Feb; 14(2):122-5. PubMed ID: 18390175
[TBL] [Abstract][Full Text] [Related]
56. Long-term effects of short hairpin RNA-targeted human telomerase reverse transcriptase on suppression of SGC-7901 cell proliferation by inhibition of telomerase activity.
Qian X; Cheng J; Chen A; Wang Y; Tao Y; Cao J; Feng Z
Oncol Rep; 2008 Feb; 19(2):575-81. PubMed ID: 18202810
[TBL] [Abstract][Full Text] [Related]
57. Radiation physics and genetic targeting: new directions for radiotherapy. The Douglas Lea Lecture 1999.
Wheldon TE
Phys Med Biol; 2000 Jul; 45(7):R77-95. PubMed ID: 10943913
[TBL] [Abstract][Full Text] [Related]
58. Targeting and killing of prostate cancer cells using lentiviral constructs containing a sequence recognized by translation factor eIF4E and a prostate-specific promoter.
Yu D; Scott C; Jia WW; De Benedetti A; Williams BJ; Fazli L; Wen Y; Gleave M; Nelson C; Rennie PS
Cancer Gene Ther; 2006 Jan; 13(1):32-43. PubMed ID: 16052226
[TBL] [Abstract][Full Text] [Related]
59. Heat-directed suicide gene therapy mediated by heat shock protein promoter for gastric cancer.
Isomoto H; Ohtsuru A; Braiden V; Iwamatsu M; Miki F; Kawashita Y; Mizuta Y; Kaneda Y; Kohno S; Yamashita S
Oncol Rep; 2006 Mar; 15(3):629-35. PubMed ID: 16465423
[TBL] [Abstract][Full Text] [Related]
60. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
Madsen MT; Bushnell DL; Juweid ME; Menda Y; O'Dorisio MS; O'Dorisio T; Besse IM
J Nucl Med; 2006 Apr; 47(4):660-7. PubMed ID: 16595501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
